<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225144</url>
  </required_header>
  <id_info>
    <org_study_id>170131</org_study_id>
    <secondary_id>17-N-0131</secondary_id>
    <nct_id>NCT03225144</nct_id>
  </id_info>
  <brief_title>Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia</brief_title>
  <official_title>Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Neurodegenerative disorders can lead to problems in movement or memory. Some can cause&#xD;
      abnormal proteins to build up in brain cells. Researchers want to understand whether these&#xD;
      diseases have related causes or risk factors.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To test people with movement or thinking and memory problems to see if they are eligible for&#xD;
      research studies.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      People ages 18 and older with a neurodegenerative disorder associated with accumulation of&#xD;
      TDP-43 or Tau proteins&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will have a screening visit. This may take place over 2-3 days. Tests include:&#xD;
&#xD;
      Medical history&#xD;
&#xD;
      Physical exam&#xD;
&#xD;
      Questions about behavior and mood&#xD;
&#xD;
      Tests of memory, attention, concentration, and thinking&#xD;
&#xD;
      Movement measurement. The speed at which participants can stand up from a chair, tap their&#xD;
      finger and foot, and walk a short distance will be measured. Some movements will be&#xD;
      videotaped. They will be videotaped while they speak and read a paragraph.&#xD;
&#xD;
      Blood tests. This might include genetic testing.&#xD;
&#xD;
      Lung and breathing tests&#xD;
&#xD;
      MRI. They will lie on a table that slides into a cylinder that takes pictures of the body.&#xD;
      Some participants will get a dye through IV.&#xD;
&#xD;
      Electromyography. A thin needle will be inserted into the muscles to measure electrical&#xD;
      signals.&#xD;
&#xD;
      Nerve tests. Small electrodes on the skin record muscle and nerve activity.&#xD;
&#xD;
      A small piece of skin may be removed.&#xD;
&#xD;
      A skin or blood sample may be taken to create stem cells.&#xD;
&#xD;
      Optional lumbar puncture. A needle will be inserted into the space between the bones of the&#xD;
      back to collect fluid.&#xD;
&#xD;
      If participants are not eligible for current studies, they may be contacted in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives&#xD;
&#xD;
      The primary objective is to evaluate patients referred with a diagnosis of frontotemporal&#xD;
      dementia (FTD), amyotrophic lateral sclerosis (ALS), or related adult-onset neurodegenerative&#xD;
      disorders to assess patient eligibility for ongoing protocols. The secondary objective is to&#xD;
      develop and maintain a registry of characterized patients and presymptopmatic carriers of&#xD;
      gene mutations that cause ALS FTD spectrum disorders. An exploratory objective is to obtain&#xD;
      biospecimens from clinically characterized patients to carry out laboratory-based studies&#xD;
      aimed at understanding the molecular pathways and genetic overlap between these&#xD;
      neurodegenerative disorders.&#xD;
&#xD;
      Study population&#xD;
&#xD;
      Adults referred with clinical diagnoses of frontotemporal dementia, motor neuron disorder, or&#xD;
      related adult-onset neurodegenerative disorder. Presymptomatic carriers of genes known to&#xD;
      cause familial FTD or ALS.&#xD;
&#xD;
      Design&#xD;
&#xD;
      All participants will undergo clinical tests to confirm diagnoses and to stage disease&#xD;
      severity, including a standard battery of tests to measure cognitive and motor function.&#xD;
      Participants may opt-in for research procedures such as phlebotomy, skin biopsy, and&#xD;
&#xD;
      lumbar puncture to obtain biospecimens for laboratory research, and magnetic resonance&#xD;
      imaging or transcranial magnetic stimulation may be used to explore biomarkers of disease.&#xD;
&#xD;
      Outcome measures&#xD;
&#xD;
      Clinical information will be analyzed as part of our research to identify common features and&#xD;
      differences among participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical information</measure>
    <time_frame>10/30/2025</time_frame>
    <description>Clinical information will be analyzed as part of our research to identify common features and differences among participants.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>patients who are referred with a diagnosis of frontotemporal dementia, motor neuron disorder, or related adult-onset neurodegenerative disorder to assess patient eligibility for ongoing protocols</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with a diagnosis of ALS, FTD, or a related adult-onset neurodegenerative disorder&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Patients will be included if they&#xD;
&#xD;
          -  Are age 18 or older&#xD;
&#xD;
          -  Have been given a diagnosis by a neurologist of frontotemporal dementia, primary&#xD;
             progressive aphasia, semantic dementia, motor neuron disorder, amyotrophic lateral&#xD;
             sclerosis, progressive bulbar palsy, corticobasal syndrome, Huntington disease or&#xD;
             other related adult-onset neurodegenerative disorder OR&#xD;
&#xD;
          -  Carry a mutation in a gene that causes familial ALS or FTD&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Patients will be excluded if they&#xD;
&#xD;
          -  Have other major neurological or medical diseases that may cause progressive weakness&#xD;
             or cognitive dysfunction, such as structural brain or spinal cord disease, metabolic&#xD;
             diseases, paraneoplastic syndromes, infectious diseases, peripheral neuropathy or&#xD;
             radiculopathy or other significant neurological abnormalities.&#xD;
&#xD;
          -  Have an unstable medical condition that, in the opinion of the investigators, makes&#xD;
             participation unsafe&#xD;
&#xD;
          -  Require daytime ventilator support at the time of study entry&#xD;
&#xD;
          -  Are unable to travel to NIH&#xD;
&#xD;
          -  Patients with pacemakers or other implanted electrical devices, brain stimulators,&#xD;
             dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic&#xD;
             prostheses (including metal pins and rods, heart valves, and cochlear implants),&#xD;
             permanent eyeliner, implanted delivery pumps, or shrapnel fragments, metal fragments&#xD;
             in the eye) will not be excluded but will not undergo magnetic resonance imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin Y Kwan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol H Hoffman</last_name>
    <phone>(301) 451-1229</phone>
    <email>carol.hoffman@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Farren</last_name>
      <phone>(301) 496-5526</phone>
      <email>jennifer.farren@nih.gov</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2017-N-0131.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Snowden JS, Adams J, Harris J, Thompson JC, Rollinson S, Richardson A, Jones M, Neary D, Mann DM, Pickering-Brown S. Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):497-505. doi: 10.3109/21678421.2015.1074700. Epub 2015 Oct 16.</citation>
    <PMID>26473392</PMID>
  </reference>
  <reference>
    <citation>Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Hölttä-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chiò A, Restagno G, Borghero G, Sabatelli M; ITALSGEN Consortium, Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011 Oct 20;72(2):257-68. doi: 10.1016/j.neuron.2011.09.010. Epub 2011 Sep 21.</citation>
    <PMID>21944779</PMID>
  </reference>
  <verification_date>September 3, 2021</verification_date>
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TDP-43</keyword>
  <keyword>Progressive Supranuclear Palsy</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <keyword>Frontotemporal Dementia</keyword>
  <keyword>Corticobasal Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

